Voluntary nationwide recall: Exela Pharma (October)
Nov. 2023Pharmacy Updates
"Exela Pharma Sciences, LLC (Exela) is recalling several lots of 8.4% Sodium Bicarbonate Injection, USP. This drug is used for the treatment of metabolic acidosis (a buildup of acid in the body).
This drug (NDC: 51754-5001-04) is being recalled because routine inspection of samples found particles of silicone. Administration of an injectable product that contains particulate matter may result in local irritation or swelling in response to the foreign material. If the particulate matter reaches the blood vessels it can travel to various organs and block blood vessels in the heart, lungs, or brain. The blockage can cause stroke and even lead to death. Read the full text of the Excela Pharma recall."
Recent Announcements
UPMC Dental Advantage celebrates 15-years of growth
From pilot program to now serving all product linesJan. 2026What's New
ACA Risk Adjustment Claims Submission Announcement
Notice: Submit your claims for ACA membersJan. 2026Important Notices
Register for the Oral Health in Your Pediatric Office CME - accredited webinar
Please join us for a live, CME-accredited webinar on Wednesday, March 11 from noon to 1 p.m. that will provide an overview of oral health in your pediatric office. Providers with a(n) MD/DO, PA, CRNP, RN, or LPN may also apply for topical fluoride certification after completion of this course.Jan. 2026Education/Webinars